<DOC>
	<DOCNO>NCT00363974</DOCNO>
	<brief_summary>The purpose study determine drug , call AEG35156 , safely give AML patient whether effectively reduce level protein ( XIAP ) increase sensitivity cancer cell chemotherapy ( ara-C idarubicin ) patient refractory relapse AML .</brief_summary>
	<brief_title>Study XIAP Antisense Given With Chemotherapy Refractory/Relapsed AML</brief_title>
	<detailed_description>This phase I/II , single-arm , open-label , study establish recommend dose activity AEG35156 administer daily x3 two-hour infusion prior reinduction chemotherapy idarubicin ara-C follow weekly two-hour AEG35156 infusion . Subjects eligible study entry must confirm diagnosis AML first relapse initial CR last less 6 month primary refractory AML . Fixed dose idarubicin ara-C give , plus one eight dos AEG35156 : 12 , 24 , 48 , 75 , 110 , 165 , 250 350mg/m2 . A maximum 54 patient treated cohort size 3 , start 12mg/m2 , skip untried dose level escalate . Following dose escalation , approximately 20 patient treat best acceptable dose determine method Thall Cook ( 2004 ) .</detailed_description>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<criteria>Inclusion Criteria Subjects relapse refractory AML , except APL ( acute promyelocytic leukemia ) , receive initial treatment first relapse initial CR last less 6 month primary refractory AML expect complete response rate ≤20 % . The initial diagnosis AML base presence &gt; 10 % blast marrow blood , diagnosis relapsed/refractory AML base presence either &gt; 10 % blast marrow blood 510 % blast either site together cytopenia ( Hb &lt; 10 g/dL , platelet &lt; 100,000 /uL , neutrophil count &lt; 1000 /uL ) . Peripheral AML blast count &lt; 50,000 /uL project rise 50,000 /uL within 5 day begin treatment . Subjects must Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 . Subjects must &gt; 18 year old . Male , female subject postmenopausal ( amenorrhagic least 12 month ) , surgically biologically sterile . Females childbearing potential negative serum pregnancy test 7296 hour prior 1st infusion study use adequate form contraception duration study , include 30 day last treatment . Adequate method contraception use male female subject . Subjects must adequate organ immune function indicate follow laboratory value : Parameter Laboratory Values Serum creatinine ; &lt; 2.0mg/dL Total Bilirubin &lt; 2.0mg/dL AST ( SGOT ) ALT ( SGPT ) &lt; 3 X ULN * *ULN : Institution 's upper limit normal . The subject must understand able willing likely fully comply study procedure , include schedule followup , restriction . The subject , subject 's legal guardian , must give write personally sign date informed consent participate study , accordance International Conference Harmonization ( ICH ) Good Clinical Practice ( GCP ) Guidelines , complete study related procedure . Exclusion Criteria Clinical evidence active CNS leukemic involvement . Patients leftventricular ejection fraction &lt; 50 % . Active uncontrolled infection . Patients infection active treatment antibiotic whose infection control may enter study . Current evidence invasive fungal infection ( blood tissue culture ) . Current evidence active second malignancy except nonmelanoma skin cancer . Uncontrolled medical problem , unrelated malignancy , sufficient severity opinion investigator , impair subject 's ability give inform consent unacceptably reduce safety propose treatment . Neurological psychiatric disorder would interfere consent study followup . Known suspected intolerance hypersensitivity study material [ closely related compound ] state ingredient . History alcohol substance abuse within last year . Use another investigational agent participation clinical trial within last 14 day prior enrolment . Subjects use previous AS agent least 90 day exclude . Female subject pregnant lactating , female positive pregnancy test screening must exclude . Subjects previously enrol study subsequently withdraw must also exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>AML</keyword>
	<keyword>leukemia</keyword>
	<keyword>relapse</keyword>
	<keyword>refractory</keyword>
	<keyword>antisense</keyword>
	<keyword>oligonucleotide</keyword>
</DOC>